New Zealand markets closed

Astria Therapeutics, Inc. (ATXS)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
13.60+0.07 (+0.52%)
At close: 04:00PM EDT
13.66 +0.06 (+0.44%)
After hours: 07:49PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close13.53
Open13.55
Bid13.62 x 300
Ask13.68 x 1000
Day's range12.83 - 13.89
52-week range4.26 - 16.90
Volume1,529,230
Avg. volume1,001,024
Market cap746.682M
Beta (5Y monthly)0.72
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE

    BOSTON, Mass., March 25, 2024--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced positive initial proof-of-concept results from the ALPHA-STAR Phase 1b/2 clinical trial evaluating STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, in hereditary angioedema (HAE) patients. Initial results demonstrate a favorable safety and tolerability profile, mean monthly attack

  • Business Wire

    Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BOSTON, March 05, 2024--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 40,000 shares of Astria’s common stock on March 1, 2024 under Astria’s 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria.

  • Business Wire

    Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

    BOSTON, March 04, 2024--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.